Pushing back an initial deadline, the US Food and Drug Administration (FDA) has proposed a new regulatory action date of 22 June, by which time the agency will assess the logistics of a possible approval for Duchenne muscular dystrophy (DMD) gene therapy.
In a press release, Sarepta said that ongoing discussions with the FDA, are weighing the therapy鈥檚 potential accelerated approval for DMD patients of ages four to five years old, possibly later expanding to a non-age-restricted label. The previous Prescription Drug User Fee Act (PDUFA) date for the gene transfer therapy delandistrogene moxeparvovec (SRP-9001) was 29 May.
DMD is a rare genetic disorder caused by changes to the dystrophin protein, leading to progressive muscular degeneration. Sarepta鈥檚 gene transfer therapy replaces the faulty gene and activates to prevent degeneration.
The FDA has told Sarepta that in this additional timeframe, it will complete final label negotiations and work out post-marketing commitments. The that a non-age-restricted expansion of the delandistrogene moxeparvovec label could be possible, depending on meeting objectives in the Phase III (NCT05096221).
The Embark study has completed enrollment and the Massachusetts-based company predicts that topline data will be available in Q4. The randomised, placebo-controlled clinical trial is investigating the primary endpoint of change from baseline in participants鈥� North Star Ambulatory Assessment (NSAA) total score. This is a standard scale in DMD that measures the performance of different functional skills.
Previously, in a 12 May FDA Advisory Committee meeting, panelists voted 8-6 in favour of the therapy鈥檚 approval. In the past, the FDA has approved Sarepta鈥檚 exon-skipping gene therapies Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) for DMD treatment. However, these therapies are only effective in those with mutations in specific exons. If approved, delandistrogene moxeparvovec will become the first transfer gene therapy available for to all DMD patients with a mutation in the dystrophin gene. Delandistrogene moxeparvovec is being developed by Sarepta in partnership with . Sarepta has said that it will remain in a quiet period for the remainder of the BLA review.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
